Drug Trial Radar · NCT07010575
Patient Preference Study: Standard of Care Versus Once-daily Trientine Tetrahydrochloride
Last checked: Nov 19, 2026Latest source record: Apr 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10
Actual
Start
Jul 15, 2025
Primary completion
Dec 18, 2025
Study completion Dec 18, 2025
Sponsor
- Lead sponsor
- OrphalanIndustry
- Sponsor type
- Industry
- First posted
- Jun 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Decentralized study to assess patient reported treatment satisfaction comparing their current standard-of-care Wilson's Disease (WD) treatment with a new once-daily Trientine (TETA) 4HCl formulation.
Conditions
- Wilson's Disease
Interventions
New TETA 4HCl FormulationDrug
Individual patient doses will depend on the Standard of Care (SOC) therapy at study entry and guided by recommended dosing switch schedule outlined in the study protocol. The dose may subsequently be titrated based on clinical response per the investigator's judgement.
Standard of CareDrug
Patients will be returned to their approved Wilson's Disease SOC therapy (dose and frequency) at study entry as prescribed by their treating Wilson's Disease physician.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assess and compare patient preference, convenience and satisfaction between current standard of care treatments for Wilson's Disease and the new TETA 4HCl formulation using patient reported outcome questionnaires.Time frame: From the screening assessment (-28 days to Day 1) to end of study at Week 8
- Assess and compare patient preference, convenience and satisfaction between current standard of care treatments for Wilson's Disease and the new TETA 4HCl formulation using patient reported outcome questionnaires.Time frame: From the screening assessment (-28 days to Day 1) to end of study at Week 8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
VCTC
Hartshorne, Derbyshire, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.